Analyze Publications Database

p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 2. Improved renal function as assessed by dynamic contrast-enhanced magnetic resonance imaging

Lenhard SC, Nerurkar SS, Schaeffer TR, Mirabile RC, Boyce RW, Adams DF, Jucker BM, Willette RN. p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 2. Improved renal function as assessed by dynamic contrast-enhanced magnetic resonance imaging. J Pharmacol Exp Ther. December 2003;307(3):939-946.

Full Text – Open Access

Publication Date
December 2003

How Analyze was Used
“Images were analyzed on a Silicon Graphics O2 Workstation … using the Analyze AVW software package (AnalyzeDirect, Lenexa, KS).”

Keywords
Albuminuria/urine
Animals
Contrast Media
Creatinine/urine
Dietary Fats/adverse effects
Endothelium, Vascular/pathology
Enzyme Inhibitors/therapeutic use
Gadolinium DTPA
Glomerular Filtration Rate/drug effects
Hypertension/drug therapy/pathology
Imidazoles/pharmacology
In Vitro Techniques
Kidney/pathology/physiopathology
Kidney Function Tests
Magnetic Resonance Imaging (MRI)
Mitogen-Activated Protein Kinases/antagonists & inhibitors
Pyrimidines/pharmacology
Rats
Rats, Inbred SHR
Sodium, Dietary/adverse effects
Stroke/genetics/physiopathology
p38 Mitogen-Activated Protein Kinases

Author Affiliation(s)
Investigative and Cardiac Biology, GlaxoSmithKline, King of Prussia, PA, US. (SCL, SSN, BMJ, RNW)

Laboratory Animal Sciences, GlaxoSmithKline, King of Prussia, PA, US. (TRS)

Safety Assessment, Cardiovascular and Urogenital Center of Excellence in Drug Discovery, GlaxoSmithKline, King of Prussia, PA, US. (RCM, RWB, DFA)

ID# 2423

Tags: , , , , , , , , , , , , , , , , , , , , ,